Literature DB >> 3158611

Tissue distribution of ciprofloxacin following oral and intravenous administration.

A Dalhoff, H U Eickenberg.   

Abstract

Ciprofloxacin distribution in muscle, subcutaneous fat and perirenal and perivesical fat was studied following a single i.v. bolus injection of 100 mg or oral administration of 500 mg. Levels in muscle were on average 0.75 mg/kg; diffusion into muscle was rapid, whereas elimination from muscle was slow. Similar peak levels were recorded in fatty tissues. However, penetration into subcutaneous fat in particular may be delayed in individual cases. Following an initial lagphase of up to one hour after i.v. injection, ciprofloxacin distribution was as efficient in these patients as in the others. Tissue levels following oral administration were monitored 12 hours after intake. On average, ciprofloxacin concentrations in serum, muscle and perirenal fat were 0.17 mg/l, 0.20 mg/kg and 0.11 mg/kg, respectively. Thus, ciprofloxacin is distributed effectively throughout the extravascular space following i.v. as well as oral administration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158611     DOI: 10.1007/bf01660419

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections.

Authors:  J Boerema; B Boll; H Muytjens; J Branolte
Journal:  J Antimicrob Chemother       Date:  1985-08       Impact factor: 5.790

2.  Intraprostatic concentrations of ciprofloxacin after intravenous administration.

Authors:  J B Boerema; F M Debruyne; A Dalhoff
Journal:  Lancet       Date:  1984-09-22       Impact factor: 79.321

3.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

5.  Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens.

Authors:  J A Hoogkamp-Korstanje; H J van Oort; J J Schipper; T van der Wal
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

6.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Diffusion of ciprofloxacin into prostatic fluid.

Authors:  A Dalhoff; W Weidner
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

8.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

9.  Ciprofloxacin distribution in prostatic tissue and fluid following oral administration.

Authors:  J B Boerema; A Dalhoff; F M Debruyne
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

10.  Ciprofloxacin concentrations in tonsils following a single intravenous infusion.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1984 Sep-Oct       Impact factor: 3.553

  10 in total
  13 in total

1.  Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.

Authors:  D Fabre; F Bressolle; R Gomeni; C Arich; F Lemesle; H Beziau; M Galtier
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

Review 2.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  Penetration of ciprofloxacin into kidney, fat, muscle and skin tissue.

Authors:  F D Daschner; M Westenfelder; A Dalhoff
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

4.  Penetration of ciprofloxacin into human lung tissue following intravenous injection.

Authors:  D Schlenkhoff; A Dalhoff; J Knopf; W Opferkuch
Journal:  Infection       Date:  1986 Nov-Dec       Impact factor: 3.553

5.  Ciprofloxacin concentrations in tonsils following single or multiple administrations.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 6.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

7.  Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers.

Authors:  H J Zeiler; D Beermann; W Wingender; D Förster; P Schacht
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 8.  Worldwide clinical data on efficacy and safety of ciprofloxacin.

Authors:  P Schacht; G Arcieri; J Branolte; H Bruck; V Chyský; E Griffith; G Gruenwaldt; R Hullmann; C A Konopka; B O'Brien
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 9.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

10.  Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia.

Authors:  G Maschmeyer; E Haralambie; W Gaus; W Kern; A W Dekker; H G De Vries-Hospers; W Sizoo; W König; F Gutzler; S Daenen
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.